Otsuka wins early FDA approval for a colorectal cancer combo drug

  • Otsuka,FDA,cancer,Lonsurf
  • fiercebiotech

Japanese drugmaker Otsuka won FDA approval for a two-drug therapy for colorectal cancer, planning to market the combination as a treatment for advanced forms of the disease.

The treatment, developed as TAS-102, combines the cancer-killing trifluridine with tipiracil, an agent designed to block enzymes that protect tumors from its partner chemical. The FDA cleared TAS-102 to treat refractory metastatic colorectal cancer, approving the therapy for patients whose tumors have spread despite first-line therapies.

Otsuka's drug met its goals in a Phase III study on 800 patients with previously treated metastatic colorectal cancer, beating placebo in extending progression-free survival, the FDA said.

The agency's approval comes almost three months ahead of schedule, underscoring the FDA's longstanding penchant for speedily signing off on new cancer treatments for the most dire patient populations.

The combo therapy is already on the market in Japan under the brand name Lonsurf. Otsuka submitted its treatment for European review in March, and the company has since signed a $130 million partnership with Servier that tasks the French drugmaker with marketing the drug on the continent.


This link:http://www.chemcd.com/news/18580.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.